How heart medications affect blood flow in hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with obstructive hypertrophic cardiomyopathy.
- You are scheduled for or willing to have a heart MRI that checks blood flow in the heart muscle.
- You are already taking the standard medications for your condition.
- You do not have severe kidney disease, liver disease, or a history of dangerous heart rhythms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This trial tests whether a person's genetic makeup can predict how well they respond to the drug mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle is thickened and blocks blood flow.
This study collects blood samples from people with obstructive hypertrophic cardiomyopathy (a type of heart muscle disease) to explore how genetics and other factors affect how well the drug mavacamten works. It may help doctors better understand who benefits most from this treatment.
Hear when a new Hypertrophic Obstructive Cardiomyopathy \(HOCM\) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.